Cite
HARVARD Citation
Friedlander, M. et al. (2018). Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. Annals of oncology. pp. 737-743. [Online].